Publications

You can use the filters to show only results that match your interests

Filter publications
404 publications by Medicines and Healthcare products Regulatory Agency ×
Get updates to this list email feed

Copy and paste this URL in to your feed reader

  1. Parallel import licenses granted in July 2018

  2. Marketing authorisations granted in July 2018

  3. Human and veterinary medicines: register of licensed manufacturing sites

  4. Register of brokers authorised to deal in human medicines

  5. Medicines: terminated and cancelled manufacturing and wholesale dealer licences

  6. Human and veterinary medicines: register of licensed wholesale distribution sites

  7. Medicines: new manufacturing and wholesale dealer licences

  8. Early access to medicines scheme applications: pending, refused, granted

    • MHRA
    • Official Statistics
  9. Suspended and revoked licences and registrations for manufacturers and wholesalers of medicines and ingredients

  10. Assistive technology: definition and safe use

  11. Early access to medicines scheme (EAMS) scientific opinion: patisiran-LNP to treat adults with hereditary transthyretin-mediated amyloidosis

  12. Clinical trials for medicines: authorisation assessment performance

    • MHRA
    • Transparency data
  13. Medicines: licensing time-based performance measures

    • MHRA
    • Official Statistics
  14. Implementation period: what it means for the life sciences sector

    • DHSC, VMD and MHRA
    • Guidance
  15. Medical devices: UK notified bodies

  16. MHRA fees

    • MHRA
    • Statutory guidance
  17. Early access to medicines scheme: expired scientific opinions

    • MHRA
    • Decision
  18. Medicines and Healthcare products Regulatory Agency board member expenses from January to March 2018

    • MHRA
    • Transparency data
  19. Medicines and Healthcare Products Regulatory Agency Annual Report and Accounts 2017 to 2018

    • MHRA
    • Corporate report
  20. Drug Safety Update: monthly PDF newsletter

    • MHRA
    • Guidance
  21. Implementing ‘safety features’ under the Falsified Medicines Directive

    • MHRA
    • Open consultation
  22. Annual review of good clinical practice referrals

    • MHRA
    • Official Statistics
  23. Marketing authorisations granted in June 2018

  24. Parallel import licenses granted in June 2018

  25. Common issues identified during clinical trial applications

    • MHRA
    • Guidance
  26. MHRA: business impact target

    • MHRA
    • Research and analysis
  27. Advertising investigations: May 2018

  28. Early access to medicines scheme (EAMS) scientific opinion: Raxone to treat the decline of respiratory function in patients with Duchenne Muscular Dystrophy

  29. Medical devices: software applications (apps)

  30. E-learning modules: medicines

    • MHRA
    • Guidance
  31. Medicines: notes for applicants and holders of a wholesale dealer licence or broker registration

  32. Medicines and Healthcare products Regulatory Agency Privacy Notice

    • MHRA
    • Transparency data
  33. Marketing authorisations granted in May 2018

  34. Parallel import licenses granted in May 2018

  35. Review Panel Annual Report 2017

    • MHRA
    • Corporate report
  36. Annual reports of the ABRHP and the HMAC

    • MHRA
    • Corporate report
  37. Early access to medicines scheme (EAMS) scientific opinion: Volanesorsen as a treatment of adult patients with familial chylomicronaemia syndrome

  38. Early access to medicines scheme (EAMS) scientific opinion: Nivolumab to treat advanced or recurrent gastric or gastroesophageal junction cancer after two or more systemic therapies

  39. Government response to report on Brexit and medicines, medical devices and substances of human origin

    • DHSC, IPO, MHRA, OLS and DExEU
    • Policy paper
  40. Human Medicines Regulations 2012 Advisory Bodies annual report 2017

    • MHRA
    • Corporate report